Amivantamab plus lazertinib versus osimertinib as first-line treatment in EGFR-mutated advanced non-small cell lung cancer: MARIPOSA Asian subset.
Journal
Lung cancer (Amsterdam, Netherlands)
Journal Volume
204
Start Page
Article number 108496
ISSN
1872-8332
Date Issued
2025-06
Author(s)
Cho, Byoung Chul
Hayashi, Hidetoshi
Lee, Jong-Seok
Lee, Se-Hoon
Danchaivijitr, Pongwut
Cheng, Ying
Liu, Baogang
Alip, Adlinda
Xiong, Hailin
How, Soon Hin
Chang, Gee-Chen
Yoshioka, Hiroshige
Nahit Şendur, Mehmet Ali
Prabhash, Kumar
Azuma, Koichi
Lee, Yun-Gyoo
Lin, Chien-Chung
Matsumoto, Shingo
Sunpaweravong, Patrapim
Xia, Yichuan
Martinez, Melissa
Bauml, Joshua M
Sethi, Seema
Lu, Shun
Abstract
The incidence of epidermal growth factor receptor (EGFR) mutations is higher among Asian patients with advanced non-small cell lung cancer than the general advanced non-small cell lung cancer population. We evaluated the efficacy and safety of amivantamab in combination with lazertinib versus osimertinib in Asian participants from the phase 3 MARIPOSA study who had treatment-naïve advanced non-small cell lung cancer with common EGFR mutations.
Participants were randomized 2:2:1 to receive amivantamab-lazertinib, osimertinib alone, or lazertinib alone. The primary endpoint was progression-free survival based on blinded independent central review per RECIST v1.1. Secondary endpoints included overall survival, objective response rate, duration of response, and safety. Exploratory endpoints included extracranial progression-free survival and post-progression outcomes.
Of 1074 randomized participants, 629 were Asian, with 250 and 251 randomized to the amivantamab-lazertinib and osimertinib arms, respectively. Among Asian participants, at a median follow-up of 22.5 months, amivantamab-lazertinib showed a 35 % reduction in the risk of disease progression or death versus osimertinib (hazard ratio, 0.65; P < 0.001). Consistent with the overall population, median progression-free survival was 27.5 and 18.3 months in the amivantamab-lazertinib and osimertinib arms, respectively. The objective response rate was 88 % for amivantamab-lazertinib versus 85 % for osimertinib. The median duration of response among confirmed responders improved by 8.6 months for amivantamab-lazertinib versus osimertinib. Favorable trends were also seen for overall survival, extracranial progression-free survival, and post-progression outcomes for amivantamab-lazertinib over osimertinib. Adverse events in Asian participants were similar to those in the overall population.
Amivantamab-lazertinib demonstrated superior progression-free survival versus osimertinib in Asian participants, with a tolerable safety profile. These results were consistent with those in the overall population.
Subjects
Amivantamab
Asian patient
EGFR TKI
EGFR-mutated NSCLC
SDGs
Type
journal article